Details for Patent: 9,669,021

« Back to Dashboard

Which drugs does patent 9,669,021 protect, and when does it expire?

Patent 9,669,021 protects KYNMOBI and is included in one NDA.

This patent has forty-seven patent family members in nineteen countries.

Summary for Patent: 9,669,021

Title:	Sublingual apomorphine
Abstract:	Disclosed are methods of treating Parkinson's disease by (i) providing a pharmaceutical composition in unit dosage form that is a film having a first portion including apomorphine particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent, where the film contains the acid addition salt of apomorphine in an amount effective to treat Parkinson's disease, and (ii) administering the film by placing the film sublingually in the mouth of the subject and contacting sublingual mucosal tissue with the film.
Inventor(s):	Anthony John Giovinazzo, David Bruce Hedden, Marc L. de Somer, Nathan John Bryson
Assignee:	Sunovion CNS Development Canada ULC , Sumitomo Pharma America Inc
Application Number:	US14/971,532
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,669,021
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

US Patent 9,669,021: Apomorphine Sublingual Film Claims, Expiration, Orange Book Status and Patent Landscape

US Patent 9,669,021 protects a method of treating Parkinson's disease with a sublingual film containing an acid-addition salt of apomorphine, a pH-neutralizing agent and defined delivery characteristics. The patent is directed primarily to KYNMOBI, Sunovion Pharmaceuticals' apomorphine hydrochloride sublingual film. Its strongest coverage is the combination of a two-portion film, sublingual administration, rapid systemic exposure and specified apomorphine dose ranges.

The patent does not broadly cover every apomorphine product. Its independent claim requires a Parkinson's treatment method using a film with both an apomorphine-containing portion and a separate pH-neutralizing portion. Products using injection, infusion, oral tablets, nasal delivery or a materially different film architecture fall outside the literal scope of claim 1.

What does US Patent 9,669,021 protect?

US Patent 9,669,021 protects a treatment method comprising two required steps:

1. Providing a unit-dose pharmaceutical film containing:

   • Apomorphine particles in an acid-addition salt form;
   • A separate portion containing a pH-neutralizing agent; and
   • An amount of apomorphine effective to treat Parkinson's disease.

2. Placing the film sublingually so that it contacts sublingual mucosal tissue.

The patent's claim structure is method-of-treatment coverage rather than a pure composition claim. A commercial product may therefore practice the patented subject matter when it is administered according to the claimed method, even if the product's physical formulation is not itself claimed in an independent composition claim.

Core claim limitations

Limitation	Claim requirement	Commercial significance
Disease	Parkinson's disease	Limits the principal method claim to Parkinson's treatment
Active ingredient	Acid-addition salt of apomorphine	Apomorphine hydrochloride is expressly claimed in claim 2
Dosage form	Film in unit dosage form	Excludes injections and conventional tablets
Film structure	First portion with apomorphine particles and second portion with pH-neutralizing agent	Creates a formulation-design limitation
Administration	Sublingual placement and mucosal contact	Supports product-specific use coverage
Particle size	Effective particle size of 1 to 10 micrometers in claim 6	Narrows the formulation to a controlled particulate form
Dose	2 to 40 mg in claim 8; narrower ranges in claims 9-12, 16 and 19	Maps closely to commercial dose strengths
Pharmacokinetics	At least 3 ng/mL average plasma concentration within 20 minutes in claim 14	Adds a performance limitation
Film architecture	First and second layers in claim 17	Captures a multilayer implementation
Effervescence	Non-effervescent unit dosage form in claim 18	Excludes effervescent delivery systems

How are claims 1 through 22 organized?

Claim 1 is the only independent claim in the supplied claim set. Claims 2 through 22 narrow claim 1 or a dependent claim.

Independent claim 1

Claim 1 is the principal infringement gate. A competing product must be assessed against every limitation:

• It must be a film.
• The film must be a unit dosage form.
• The apomorphine must be in an acid-addition salt form.
• The film must have an apomorphine-containing first portion.
• It must have a second portion containing a pH-neutralizing agent.
• The film must be used sublingually.
• The claimed method must treat Parkinson's disease.

The phrase "first portion" and "second portion" is broader than "first layer" and "second layer." Claim 1 can potentially cover portions arranged within a film without requiring a discrete bilayer. Claim 17 narrows the structure to two layers.

Formulation and ingredient claims

Claims 2 through 7 add formulation characteristics:

• Claim 2: apomorphine hydrochloride.
• Claim 3: antioxidant.
• Claim 4: permeation enhancer.
• Claim 5: glycerol monostearate.
• Claim 6: 1-10 micrometer effective particle size.
• Claim 7: polysaccharide.

These claims create fallback positions if a court narrows the broader formulation language in claim 1. A product can avoid some dependent claims by omitting a listed excipient, but that does not avoid claim 1 if all independent-claim limitations remain present.

Dose claims

Claims 8 through 12, 16 and 19-22 cover dose ranges:

Claim	Claimed apomorphine salt amount
8	2-40 mg
9	12 ± 3 mg, or approximately 9-15 mg
10	22 ± 4 mg, or approximately 18-26 mg
11	30 ± 5 mg, or approximately 25-35 mg
12	35 ± 5 mg, or approximately 30-40 mg
16	15 ± 3 mg, or approximately 12-18 mg
19	12-30 mg
20	Claim 19 plus apomorphine hydrochloride
21	Claim 17 plus 12-30 mg
22	Claim 21 plus apomorphine hydrochloride

The dose claims are commercially important because KYNMOBI was supplied in 10 mg, 15 mg, 20 mg and 30 mg apomorphine strengths. The patent claims use the amount of acid-addition salt, not necessarily the free-base equivalent. A product-by-product assessment must therefore distinguish apomorphine hydrochloride mass from apomorphine free-base mass.

What formulations are protected by US 9,669,021?

The patent protects a sublingual film that separates the apomorphine-containing region from a pH-neutralizing region. The second region may be a discrete layer or another defined portion of the film.

The formulation architecture addresses a technical problem associated with apomorphine salts. Apomorphine hydrochloride is acidic and has limited suitability for direct mucosal delivery unless the formulation manages local pH, dissolution and permeation. The claimed pH-neutralizing agent is therefore a central limitation rather than a peripheral excipient.

Potentially covered formulation features

The dependent claims identify several formulation strategies:

• Apomorphine hydrochloride;
• Antioxidants to limit oxidative degradation;
• Permeation enhancers;
• Glycerol monostearate;
• Polysaccharides;
• Mucoadhesive polymers;
• Micronized apomorphine particles;
• Bilayer construction;
• Non-effervescent delivery;
• Rapid plasma exposure.

The patent does not require every listed feature. Claims 3-7, 13 and 15 separately narrow the claim set. A product containing an antioxidant but no permeation enhancer could fall within claim 3 but not claim 4. A product using a single homogeneous layer may avoid claim 17 while still implicating claim 1 if it has distinguishable first and second portions.

How strong is the patent estate for KYNMOBI?

US 9,669,021 has meaningful product-specific value because the claim combines the active ingredient, dosage form, route of administration and formulation architecture. Its strength is highest against a direct copy of KYNMOBI or a product whose FDA label instructs sublingual use of an apomorphine hydrochloride film.

Strengths

• The claim targets a commercially identifiable product configuration.
• Apomorphine hydrochloride is expressly covered.
• The claim reaches both formulation supply and labeled sublingual use through method-of-treatment language.
• The dose claims correspond to commercially relevant strengths.
• The rapid-exposure limitation may support infringement if product labeling or clinical evidence establishes the claimed concentration.
• The bilayer and non-effervescent limitations provide narrower positions during validity or infringement disputes.

Limitations

• Claim 1 requires a film, limiting coverage against injectable and infusion products.
• The claim requires two portions, which creates a design-around opportunity.
• A competing sponsor could investigate a single-phase film, a different pH-control system or a non-acid-addition form of apomorphine.
• Claim 14 requires a specific pharmacokinetic result. It may require clinical or pharmacokinetic evidence and is not necessarily established from formulation composition alone.
• Method claims can present enforcement challenges where the product label does not instruct the patented administration method.

The patent is stronger as a blocking right against a labeled apomorphine sublingual film than as a broad platform patent covering all noninvasive apomorphine delivery.

What is the Orange Book status of US 9,669,021?

US 9,669,021 was listed in the FDA Orange Book for KYNMOBI, the NDA product containing apomorphine hydrochloride in a sublingual film dosage form. The relevant NDA is 210875, held by Sunovion Pharmaceuticals Inc. The FDA approved KYNMOBI on May 21, 2020 for the acute, intermittent treatment of "off" episodes in patients with Parkinson's disease.

The Orange Book listing gives the patent regulatory significance beyond ordinary patent enforcement. An ANDA applicant seeking approval of a generic equivalent would generally need to address listed patents through one of the statutory certification pathways, including a Paragraph IV certification if the applicant contends that the patent is invalid, unenforceable or not infringed. The precise regulatory effect depends on the patent listing, use code and the ANDA applicant's proposed labeling. [1][2]

Regulatory milestones

Event	Date
Earliest claimed priority	June 11, 2012
US patent grant	August 29, 2017
KYNMOBI FDA approval	May 21, 2020
Regulatory product	NDA 210875
Active ingredient	Apomorphine hydrochloride
Dosage form	Sublingual film
Primary use	Acute treatment of Parkinson's disease "off" episodes
Expected patent expiration	June 11, 2033

The June 11, 2033 expiration date reflects the patent family's effective filing chronology. Any term adjustment, terminal disclaimer or other USPTO-recorded term event must be checked against the official patent term record before relying on the date for a launch decision. Patent-term extension for the product should not be assumed without an applicable regulatory record.

When does US Patent 9,669,021 lose exclusivity?

The expected expiration date is June 11, 2033. The patent issued in 2017 and has a 20-year term measured from the applicable nonprovisional or international filing date, rather than from the grant date. The patent therefore does not expire in 2037 merely because it issued in 2017.

Patent expiration is separate from FDA regulatory exclusivity. KYNMOBI received approval in 2020, and any five-year new chemical entity exclusivity would have ended in 2025. That regulatory exclusivity period does not eliminate the patent. A generic applicant may still face the listed patent until expiration or successful resolution of a Paragraph IV challenge.

The practical generic-entry date could be earlier if:

• A Paragraph IV challenge succeeds;
• The patent is held invalid or unenforceable;
• The parties settle on an authorized generic or licensed entry date;
• The patent is not properly listed for the relevant ANDA use;
• A competing product does not infringe the asserted claims.

Which companies are challenging the KYNMOBI patent?

No publicly established Paragraph IV litigation or final settlement involving US 9,669,021 is identified in the supplied record. A definitive challenge assessment requires review of current FDA Paragraph IV notices, Orange Book listings, ANDA litigation under the Hatch-Waxman statute and federal court dockets.

The absence of an identified public challenge does not convert the patent into an uncontested right. Generic manufacturers can prepare Paragraph IV certifications and litigation may follow after a notice letter. The commercial probability of challenge is constrained by the small market for apomorphine rescue therapy, the complexity of a sublingual film and the need to demonstrate pharmaceutical equivalence to the reference product.

What patent litigation affects US 9,669,021?

The principal litigation risk is likely to arise through a Hatch-Waxman action under 21 U.S.C. § 355(j)(5)(B)(iii), if an ANDA applicant certifies that the patent is invalid, unenforceable or not infringed. A filing by the NDA holder within the statutory period can trigger a 30-month stay of FDA approval, subject to statutory exceptions. [3]

The likely disputed issues would include:

1. Whether the generic film has a distinct apomorphine portion and pH-neutralizing portion.
2. Whether the pH-control component is an "organic base" where claims 13, 20 and 22 are asserted.
3. Whether the proposed product is a non-effervescent unit dosage form.
4. Whether the generic's apomorphine particle size falls within claim 6.
5. Whether the label induces sublingual administration for Parkinson's disease.
6. Whether the product produces the plasma concentration required by claim 14.
7. Whether the asserted claims are enabled and supported across the full claimed dose and formulation ranges.

Because the claims are method claims, the label and prescribing instructions will be central evidence. A generic label that omits the patented use may reduce induced-infringement exposure, but it may also undermine approval if the omitted use is inseparable from the reference product's approved indication.

What generic entry risks exist for apomorphine sublingual film?

The most credible generic-entry scenario is a direct KYNMOBI substitute using the same or substantially similar film technology. That product would face the highest risk under claims 1, 2, 8 and 19-22.

Generic design-around options

Design approach	Potential effect on 9,669,021 risk
Injectable apomorphine	Avoids the film and sublingual limitations
Continuous subcutaneous infusion	Avoids the claimed dosage form and route
Buccal rather than sublingual delivery	May avoid literal sublingual administration, depending on actual use
Single homogeneous film	May challenge the first-portion/second-portion limitation
Different active form	May avoid acid-addition-salt claims, subject to formulation and clinical constraints
Dose outside the narrower ranges	Avoids certain dependent claims but not claim 1 or claim 8 if within 2-40 mg
Alternative pH-control strategy	May avoid claims directed to organic bases, but not necessarily claim 1
Different particle size	Avoids claim 6 only

A design-around must be assessed against the entire patent family, not US 9,669,021 alone. A company that avoids this patent through a modified film may still encounter composition, manufacturing, formulation or method-of-use patents covering related apomorphine products.

How does KYNMOBI compare with competing apomorphine products?

Product	Active ingredient	Route	Dosage form	Relationship to US 9,669,021
KYNMOBI	Apomorphine hydrochloride	Sublingual	Film	Direct commercial target
APOKYN	Apomorphine hydrochloride	Subcutaneous injection	Injection	Outside film limitation
Onapgo	Apomorphine hydrochloride	Continuous subcutaneous infusion	Infusion system	Outside film and sublingual limitations
Generic apomorphine injection	Apomorphine hydrochloride	Subcutaneous	Injection	Generally outside claim 1

Apomorphine is a small molecule, so biosimilar risk does not apply. The competitive issue is generic and 505(b)(2) competition, not biosimilar substitution. Injectable and infusion products compete clinically but do not directly replicate the patented sublingual film technology.

What licensing deals and ownership changes affect the patent?

Cynapsus Therapeutics developed the sublingual apomorphine film technology and was acquired by Sunovion Pharmaceuticals in 2016. The transaction transferred the development program and associated intellectual property to Sunovion. [4]

Sunovion later commercialized KYNMOBI in the United States. Ownership and licensing analysis should distinguish:

• Original inventorship and assignment;
• Acquisition-related transfer of the patent family;
• NDA ownership;
• Any later commercialization, distribution or regional licensing arrangements;
• Patent assignment records recorded with the USPTO.

The acquisition is commercially relevant because it links the patent estate to the product sponsor, but it does not by itself establish that every related patent has identical ownership or expiration.

What manufacturing and IP barriers does the patent create?

The patent creates a manufacturing barrier around a multi-component sublingual film with controlled apomorphine particle size, pH management and rapid mucosal absorption. A generic manufacturer must reproduce the reference product's quality attributes while avoiding the claim limitations or preparing to defend a Paragraph IV position.

Key technical barriers include:

• Uniform distribution of micronized apomorphine particles;
• Physical separation or controlled arrangement of the pH-neutralizing region;
• Film strength and handling characteristics;
• Dose uniformity across narrow unit-dose ranges;
• Protection against apomorphine oxidation;
• Sublingual disintegration and residence time;
• Bioequivalence and pharmacokinetic performance;
• Manufacturing scale-up for a layered or segmented film.

These barriers can delay entry even if the patent is ultimately vulnerable. The most important technical question is whether a competing film necessarily has a first portion containing apomorphine and a second portion containing the pH-neutralizing agent. If that architecture is inherent to the product's manufacturing process, a formulation change may be required rather than a label-only change.

Key Takeaways

• US 9,669,021 is a method-of-treatment patent covering sublingual administration of an apomorphine acid-addition-salt film for Parkinson's disease.
• Claim 1 requires a film with an apomorphine portion and a separate pH-neutralizing portion.
• Apomorphine hydrochloride, micronized particles, antioxidants, permeation enhancers, glycerol monostearate, polysaccharides and mucoadhesive polymers are covered through dependent claims.
• Dose coverage includes 2-40 mg, with narrower ranges corresponding to commercial KYNMOBI strengths.
• The expected patent expiration date is June 11, 2033.
• KYNMOBI received FDA approval on May 21, 2020 under NDA 210875 and was associated with the patent in the Orange Book.
• The patent creates direct risk for a generic KYNMOBI film but limited risk for injectable or infusion apomorphine products.
• No publicly established Paragraph IV litigation or settlement involving this patent is identified in the supplied record.
• Biosimilar competition is not relevant because apomorphine is a small-molecule active ingredient.
• The principal design-around opportunities are a different film architecture, route, active form or pH-control strategy.

FAQs about US Patent 9,669,021 and KYNMOBI

Does US 9,669,021 cover apomorphine injections?

No. The claims require a film administered sublingually. Subcutaneous injection products such as APOKYN generally do not satisfy those dosage-form and route limitations.

Does the patent cover every sublingual apomorphine product?

No. The product must satisfy the claimed film and two-portion formulation requirements, including a portion containing apomorphine and a portion containing a pH-neutralizing agent.

Is US 9,669,021 a composition patent?

The supplied claims are method claims. They protect administering the claimed film to treat Parkinson's disease rather than claiming only the film as a standalone composition.

Can a generic launch before June 2033?

Yes, but only if the generic avoids infringement, invalidates the patent, obtains a settlement or license permitting earlier entry, or otherwise satisfies the applicable FDA and patent requirements.

Are biosimilars a competitive threat to KYNMOBI?

No. Apomorphine is a small-molecule drug. The relevant competitors are generics, 505(b)(2) products and alternative apomorphine delivery systems.

References

1. U.S. Food and Drug Administration. (2020). KYNMOBI (apomorphine hydrochloride) sublingual film prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).

4. Sunovion Pharmaceuticals Inc. (2016). Sunovion completes acquisition of Cynapsus Therapeutics. Corporate transaction announcement.

5. United States Patent and Trademark Office. (2017). U.S. Patent No. 9,669,021, Sublingual apomorphine formulations. USPTO.

Drugs Protected by US Patent 9,669,021

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-001	May 21, 2020		DISCN	Yes	No	9,669,021					TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-002	May 21, 2020		DISCN	Yes	No	9,669,021					TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-003	May 21, 2020		DISCN	Yes	No	9,669,021					TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

International Family Members for US Patent 9,669,021

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010259971
Australia	2017200329
Australia	2019200308